137 related articles for article (PubMed ID: 28382859)
1. Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers.
Li J; Chen H; Curcuru JR; Patel S; Johns TO; Patel D; Qian H; Jiang SW
Curr Drug Targets; 2017; 18(10):1158-1164. PubMed ID: 28382859
[TBL] [Abstract][Full Text] [Related]
2. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
4. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
Scaletta G; Plotti F; Luvero D; Capriglione S; Montera R; Miranda A; Lopez S; Terranova C; De Cicco Nardone C; Angioli R
Expert Rev Anticancer Ther; 2017 Sep; 17(9):827-839. PubMed ID: 28756722
[TBL] [Abstract][Full Text] [Related]
5. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.
Qu W; Li J; Duan P; Tang Z; Guo F; Chen H; Zhu X; Jiang SW
Expert Rev Mol Diagn; 2016 Dec; 16(12):1271-1282. PubMed ID: 27784171
[TBL] [Abstract][Full Text] [Related]
6. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
7. The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
Plotti F; Scaletta G; Terranova C; Montera R; De Cicco Nardone C; Luvero D; Rossini G; Gatti A; SchirĂ² T; Moncelli M; Guzzo F; Angioli R
Minerva Ginecol; 2019 Feb; 71(1):36-43. PubMed ID: 30318876
[TBL] [Abstract][Full Text] [Related]
8. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
[TBL] [Abstract][Full Text] [Related]
9. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
10. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract][Full Text] [Related]
11. The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis.
Gao L; Cheng HY; Dong L; Ye X; Liu YN; Chang XH; Cheng YX; Chen J; Ma RQ; Cui H
J Int Med Res; 2011; 39(5):1645-60. PubMed ID: 22117965
[TBL] [Abstract][Full Text] [Related]
12. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
13. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.
Deng L; Gao Y; Li X; Cai M; Wang H; Zhuang H; Tan M; Liu S; Hao Y; Lin B
J Exp Clin Cancer Res; 2015 Sep; 34(1):96. PubMed ID: 26362938
[TBL] [Abstract][Full Text] [Related]
15. Recombinant HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines.
Lu Q; Chen H; Senkowski C; Wang J; Wang X; Brower S; Glasgow W; Byck D; Jiang SW; Li J
Oncol Rep; 2016 Jan; 35(1):163-70. PubMed ID: 26497244
[TBL] [Abstract][Full Text] [Related]
16. HE4-test of urine and body fluids for diagnosis of gynecologic cancer.
Qu W; Gao Q; Chen H; Tang Z; Zhu X; Jiang SW
Expert Rev Mol Diagn; 2017 Mar; 17(3):239-244. PubMed ID: 28117603
[TBL] [Abstract][Full Text] [Related]
17. Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.
He Y; Wang J; Ma CX; Kang YH
Technol Cancer Res Treat; 2020; 19():1533033820971660. PubMed ID: 33148127
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
Capriglione S; Luvero D; Plotti F; Terranova C; Montera R; Scaletta G; SchirĂ² T; Rossini G; Benedetti Panici P; Angioli R
Med Oncol; 2017 Aug; 34(9):164. PubMed ID: 28825178
[TBL] [Abstract][Full Text] [Related]
19. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
20. HE4 as a biomarker for ovarian and endometrial cancer management.
Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]